[1] McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O'Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K. Diagnosis and management of dementia with Lewy bodies:fourth consensus report of the DLB Consortium[J]. Neurology, 2017, 89:88-100. [2] Neurodegenerative Diseases Committee of the Chinese Society of Microcirculation. Guidelines for the diagnosis and treatment of dementia with Lewy bodies in China[J]. Zhonghua Lao Nian Yi Xue Za Zhi, 2021, 40:1473-1484.[中国微循环学会神经变性病专业委员会. 中国路易体痴呆诊断与治疗指南[J]. 中华老年医学杂志, 2021, 40:1473-1484.] [3] Inagawa Y, Shimizu S, Takenoshita N, Tsugawa A, Hirose D, Kanbayashi T, Imanishi A, Sakurai H, Hanyu H, Kanetaka H, Hirao K. Association between cerebrospinal fluid Orexin A level and severity of rapid eye movement sleep behaviour disorder in dementia with Lewy bodies[J]. Psychogeriatrics, 2021, 21:128-130. [4] Huang S, Zhao Z, Ma J, Hu S, Li L, Wang Z, Sun W, Shi X, Li M, Zheng J. Increased plasma orexin-A concentrations are associated with the non-motor symptoms in Parkinson's disease patients[J]. Neurosci Lett, 2021, 741:135480. [5] Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, Weintraub D. Parkinson disease-associated cognitive impairment[J]. Nat Rev Dis Primers, 2021, 7:47. [6] Barateau L, Pizza F, Plazzi G, Dauvilliers Y. Narcolepsy[J]. J Sleep Res, 2022, 31:e13631. [7] Gan J, Chen Z, Han J, Ma L, Liu S, Wang XD, Ji Y. Orexin-A in patients with Lewy body disease:a systematic review and meta-analysis[J]. Front Endocrinol (Lausanne), 2021, 12:765701. [8] Lessig S, Ubhi K, Galasko D, Adame A, Pham E, Remidios K, Chang M, Hansen LA, Masliah E. Reduced hypocretin (orexin) levels in dementia with Lewy bodies[J]. Neuroreport, 2010, 21:756-760. [9] Wang Q, Cao F, Wu Y. Orexinergic system in neurodegenerative diseases[J]. Front Aging Neurosci, 2021, 13:713201. [10] Gan J, Liu S, Chen Z, Yang Y, Ma L, Meng Q, Wang XD, Liu C, Li X, Zhang W, Ji Y. Elevated plasma orexin-A levels in prodromal dementia with Lewy bodies[J]. J Alzheimers Dis, 2022, 88:1037-1048. [11] Folstein MF, Folstein SE, McHugh PR. "Mini-mental state":a practical method for grading the cognitive state of patients for the clinician[J]. J Psychiatr Res, 1975, 12:189-198. [12] Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA:a brief screening tool for mild cognitive impairment[J]. J Am Geriatr Soc, 2005, 53:695-699. [13] Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia[J]. Br J Psychiatry, 1982, 140:566-572. [14] Chen P, Yu ES, Zhang M, Liu WT, Hill R, Katzman R. ADL dependence and medical conditions in Chinese older persons:a population-based survey in Shanghai, China[J]. J Am Geriatr Soc, 1995, 43:378-383. [15] Hamilton M. A rating scale for depression[J]. J Neurol Neurosurg Psychiatry, 1960, 23:56-62. [16] Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory:comprehensive assessment of psychopathology in dementia[J]. Neurology, 1994, 44:2308-2314. [17] Congress of Neuro-Degenerative Diseases Committee of the Chinese Society of Microcirculation. Chinese experts consensus on the optimized application of PET imaging in the diagnosis of dementia (2021 edition)[J]. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2021, 21:918-926.[中国微循环学会神经变性病专业委员会. 痴呆诊断中PET临床合理化应用中国专家共识(2021版)[J]. 中国现代神经疾病杂志, 2021, 21:918-926.] [18] Kasanuki K, Iseki E, Kondo D, Fujishiro H, Minegishi M, Sato K, Katsuse O, Hino H, Kosaka K, Arai H. Neuropathological investigation of hypocretin expression in brains of dementia with Lewy bodies[J]. Neurosci Lett, 2014, 569:68-73. [19] Wennström M, Londos E, Minthon L, Nielsen HM. Altered CSF orexin and α-synuclein levels in dementia patients[J]. J Alzheimers Dis, 2012, 29:125-132. [20] Yuan Y, Zhang Y, Cheng Y, Hou Y, Huang Z, Ma J, Li N, Zhan S. Cerebrospinal fluid TNF-α and orexin in patients with Parkinson's disease and rapid eye movement sleep behavior disorder[J]. Front Neurol, 2022, 13:826013. [21] Fronczek R, Overeem S, Lee SY, Hegeman IM, van Pelt J, van Duinen SG, Lammers GJ, Swaab DF. Hypocretin (orexin) loss in Parkinson's disease[J]. Brain, 2007, 130(Pt 6):1577-1585. [22] Mishima T, Kasanuki K, Koga S, Castanedes-Casey M, Wszolek ZK, Tsuboi Y, Dickson DW. Reduced orexin immunoreactivity in Perry syndrome and multiple system atrophy[J]. Parkinsonism Relat Disord, 2017, 42:85-89. [23] Zhu Y, He J, Shi J, Wang Y, Ma L, Gou H, Chen Y, Zhu Y. Significance of determining plasma orexin levels and analysis of related factors for the diagnosis of patients with narcolepsy[J]. Sleep Med, 2020, 74:141-144. [24] Dauvilliers Y, Barateau L, Middleton B, van der Veen DR, Skene DJ. Metabolomics signature of patients with narcolepsy[J]. Neurology, 2022, 98:e493-505. [25] Dong LL, Liu XQ. Advances in neurobiologieal study on narcolepsy and its future orientation[J]. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2005, 5:256-258.[董立羚, 刘秀琴. 发作性睡病的神经生物学研究进展及未来研究方向[J]. 中国现代神经疾病杂志, 2005, 5:256-258.] [26] Stanojlovic M, Pallais JP, Lee MK, Kotz CM. Pharmacological and chemogenetic orexin/hypocretin intervention ameliorates Hipp-dependent memory impairment in the A53T mice model of Parkinson's disease[J]. Mol Brain, 2019, 12:87. [27] Cersosimo MG, Benarroch EE, Raina GB. Lewy bodies in the olfactory system and the hypothalamus[J]. Handb Clin Neurol, 2021, 182:235-244. [28] Morales-Mulia S, Magdaleno-Madrigal VM, Nicolini H, Genis-Mendoza A, Morales-Mulia M. Orexin-A up-regulates dopamine D2 receptor and mRNA in the nucleus accumbens Shell[J]. Mol Biol Rep, 2020, 47:9689-9697. [29] Perez SM, Lodge DJ. Orexin modulation of VTA dopamine neuron activity:relevance to schizophrenia[J]. Int J Neuropsychopharmacol, 2021, 24:344-353. [30] Kumar S, Behl T, Sehgal A, Singh S, Sharma N, Bhatia S, Al-Harassi A, Abdel-Daim MM, Bungau S. Exploring the role of orexinergic neurons in Parkinson's disease[J]. Neurotox Res, 2021, 39:2141-2153. [31] Baumann CR, Dauvilliers Y, Mignot E, Bassetti CL. Normal CSF hypocretin-1(orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness[J]. Eur Neurol, 2004, 52:73-76. [32] Peng B, Yang Q, B Joshi R, Liu Y, Akbar M, Song BJ, Zhou S, Wang X. Role of alcohol drinking in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis[J]. Int J Mol Sci, 2020, 21:2316. [33] Zhang D, Jiang H, Xie J. Alcohol intake and risk of Parkinson's disease:a meta-analysis of observational studies[J]. Mov Disord, 2014, 29:819-822. [34] Mitchell E, Chohan H, Bestwick JP, Noyce AJ. Alcohol and Parkinson's disease:a systematic review and meta-analysis[J]. J Parkinsons Dis, 2022, 12:2369-2381. [35] Marxen M, Gan G, Schwarz D, Mennigen E, Pilhatsch M, Zimmermann US, Guenther M, Smolka MN. Acute effects of alcohol on brain perfusion monitored with arterial spin labeling magnetic resonance imaging in young adults[J]. J Cereb Blood Flow Metab, 2014, 34:472-479. [36] Vore AS, Deak T. Alcohol, inflammation, and blood-brain barrier function in health and disease across development[J]. Int Rev Neurobiol, 2022, 161:209-249. [37] Siqueira M, Stipursky J. Blood brain barrier as an interface for alcohol induced neurotoxicity during development[J]. Neurotoxicology, 2022, 90:145-157. [38] Abbott RD, Ross GW, Duda JE, Shin C, Uyehara-Lock JH, Masaki KH, Launer LJ, White LR, Tanner CM, Petrovitch H. Excessive daytime sleepiness and topographic expansion of Lewy pathology[J]. Neurology, 2019, 93:e1425-1432. [39] Postuma RB, Iranzo A, Hu M, Högl B, Boeve BF, Manni R, Oertel WH, Arnulf I, Ferini-Strambi L, Puligheddu M, Antelmi E, Cochen De Cock V, Arnaldi D, Mollenhauer B, Videnovic A, Sonka K, Jung KY, Kunz D, Dauvilliers Y, Provini F, Lewis SJ, Buskova J, Pavlova M, Heidbreder A, Montplaisir JY, Santamaria J, Barber TR, Stefani A, St Louis EK, Terzaghi M, Janzen A, Leu-Semenescu S, Plazzi G, Nobili F, Sixel-Doering F, Dusek P, Bes F, Cortelli P, Ehgoetz Martens K, Gagnon JF, Gaig C, Zucconi M, Trenkwalder C, Gan-Or Z, Lo C, Rolinski M, Mahlknecht P, Holzknecht E, Boeve AR, Teigen LN, Toscano G, Mayer G, Morbelli S, Dawson B, Pelletier A. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder:a multicentre study[J]. Brain, 2019, 142:744-759. [40] Fan JK, Wang MC, Yang HM, Zhang JN, Gu L, Zhang H. α-Synuclein induced the occurrence of RBD via interaction with OX1R and modulated its degradation[J]. Neuromolecular Med, 2023.[Epub ahead of print] [41] Kouri I, Kolla BP, Morgenthaler TI, Mansukhani MP. Frequency and outcomes of primary central sleep apnea in a population-based study[J]. Sleep Med, 2020, 68:177-183. [42] Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle[J]. Science, 2009, 326:1005-1007. [43] Chong PLH, Garic D, Shen MD, Lundgaard I, Schwichtenberg AJ. Sleep, cerebrospinal fluid, and the glymphatic system:a systematic review[J]. Sleep Med Rev, 2022, 61:101572. [44] Lucey BP, Liu H, Toedebusch CD, Freund D, Redrick T, Chahin SL, Mawuenyega KG, Bollinger JG, Ovod V, Barthélemy NR, Bateman RJ. Suvorexant acutely decreases tau phosphorylation and Aβ in the human CNS[J]. Ann Neurol, 2023.[Epub ahead of print] [45] Guo P, Zhang WJ, Lian TH, Zhang WJ, He MY, Zhang YN, Huang Y, Ding DY, Guan HY, Li JH, Li DN, Luo DM, Zhang WJ, Yue H, Wang XM, Zhang W. Alzheimer's disease with sleep insufficiency:a cross-sectional study on correlations among clinical characteristics, orexin, its receptors, and the blood-brain barrier[J]. Neural Regen Res, 2023, 18:1757-1762. |